Australia Medicinal Cannabis Testing Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035)

Market Overview

The Australia medicinal cannabis testing market is shaped by an unusual regulatory structure. More than 99% of medicinal cannabis prescribed in Australia is unapproved, so product quality rests on sponsor declarations, GMP and laboratory evidence rather than pre-market evaluation.

Three forces are shaping demand: TGO 93 and mandatory GMP, which require every released batch to be tested; prescribing scale, with Special Access Scheme Category B approvals rising from 57,711 in 2020 to 177,762 in 2024; and the TGA review that opened on 11 August 2025.

In April 2026, the TGA published its feedback update on that review, and in June 2026 Little Green Pharma completed its Cannatrek merger. In July 2026, Cann Group reported an A1 compliance rating for its Mildura GMP facility.

Key Market Trends and Insights

• Unapproved product base: The TGA's August 2025 consultation paper counted more than 1,000 unapproved medicinal cannabis products, while only two cannabis medicines sit on the ARTG.
• Approval growth: Special Access Scheme Category B approvals reached 177,762 in 2024, up from 57,711 in 2020, widening the volume of batches needing release testing.
• Licensed producer base: The Office of Drug Control's 2026 list shows 34 licence holders, 33 for cultivation and 20 for manufacture, each needing in-process and release testing.
• Distribution scale: Burleigh Heads Cannabis sold 507,799 units through Canview in the half-year to December 2025, reported by Vitura Health in February 2026.

Australia Medicinal Cannabis Testing Market Size and Forecast

The market is moving from sample-by-sample compliance checking towards routine, programme-based quality assurance. Potency and cannabinoid profiling leads revenue today because every released batch carries a declared content, while stability testing advances fastest as shelf-life evidence and export readiness gain weight. Dried flower remains the largest sample type, and capsules, edibles and other formulations grow fastest from a small base as the regulator scrutinises novel dosage forms. Importers and sponsors expand quickest as responsibility shifts towards the product supplier. Victoria remains the largest region because of its concentration of producers and contract laboratories, and Queensland builds fastest on distribution and pharmacy growth. Price pressure on products pushes buyers to seek efficient, accredited laboratory partners.

Key Takeaways: Australia Medicinal Cannabis Testing Market

Regulatory Scrutiny Anchors Long-Term Testing Demand

Revenue should grow from AUD 42.50 million in 2025 to AUD 96.98 million in 2035 at an 8.6% CAGR, supported by TGO 93 compliance, GMP rules and tighter TGA oversight.

Stability And New Formulations Lead Growth

Potency profiling holds the largest share, but stability testing grows at an estimated 11.4% CAGR and capsules, edibles and other formulations at 10.2%, as sponsors document shelf life and novel dosage forms.

Compliant Producers Gain From Quality Scrutiny

Companies with audited GMP sites and large product ranges are best placed to commission recurring testing programmes.

• Cann Group: A1 TGA GMP rating, reported in July 2026
• Little Green Pharma: 72 products in market after the June 2026 merger
• Vitura Health: 507,799 units sold through Canview in half-year to December 2025

Australia Medicinal Cannabis Testing Market Report Summary

Key Insight

Testing demand is regulatory rather than discretionary. TGO 93, GMP rules and tighter oversight keep batch testing mandatory, while segments expand at different speeds through 2035.

Key Trends in the Australia Medicinal Cannabis Testing Market

The Australia medicinal cannabis testing market is being reshaped by regulatory review, import price pressure, falling product prices and the audited GMP standing of domestic producers.

July 2026 - Cann Group Reports A1 TGA GMP Rating For Mildura Facility

• Cann Group's quarterly report of 30 July 2026 said a TGA GMP surveillance inspection rated its Mildura facility A1, good compliance, with no critical or major deficiencies.
• The company noted that prices remain under pressure from imports from Canada and Thailand, and that UK and European GMP recognition is valued by customers.
• Audited sites and mutual recognition keep release and stability testing in scope for exporters.

April 2026 - TGA Publishes Feedback Update On Unapproved Cannabis Review

• The TGA's consultation page, updated on 21 April 2026, recorded 786 submissions and broad agreement that the access framework is not fit-for-purpose and not proportionate.
• Stakeholders supported stronger enforcement of quality standards, device standards and better packaging and labelling.
• The TGA committed to education, prescriber reminders and further consultation on any proposed reforms.

February 2026 - Vitura Health Reports Falling Medicinal Cannabis Prices

• Vitura Health's half-year results of 25 February 2026 attributed lower normalised EBITDA of A$1.9 million partly to falling medicinal cannabis prices.
• Burleigh Heads Cannabis sold 507,799 units through Canview, which serves roughly 4,700 pharmacies.
• Thinner margins push sponsors to seek efficient, accredited laboratory arrangements.

August 2025 - TGA Opens Consultation On Unapproved Medicinal Cannabis

• The TGA opened a consultation on 11 August 2025, with submissions closing on 7 October 2025, to review safety and oversight of unapproved products.
• Its paper identified over 1,000 unapproved products and noted that TGO 93 does not apply to medicinal cannabis devices.
• Proposals included stronger quality oversight and standardised labelling, both of which raise analytical verification needs.

Key Insight

Regulation drives the testing agenda. Audited GMP sites, the TGA's open review of unapproved products and weaker product prices all push sponsors towards documented, recurring quality evidence.

Recent Market Developments in the Australia Medicinal Cannabis Testing Market

Recent developments, presented from the most recent, show producers consolidating, adjusting leadership and protecting the GMP facilities that generate recurring testing demand.

August 2026 - Little Green Pharma Appoints CFO After Cannatrek Merger

• Little Green Pharma announced on 20 August 2026 that Jennifer Pilcher would become Chief Financial Officer from 24 August 2026.
• Ms Pilcher spent six years at Cann Group, the last two as chief executive, and will support post-merger integration.
• The group's 2026 annual meeting on 13 August 2026 re-elected directors Brent Dennison, Thomas Huppert and Seth Yakatan.

June 2026 - Little Green Pharma Completes Cannatrek Acquisition

• Little Green Pharma announced on 1 June 2026 that its scheme of arrangement to acquire Cannatrek had been implemented after Federal Court approval on 25 May 2026.
• The combined group has AU-GMP certified manufacturing, including one of Australia's largest AU-GMP certified facilities from Cannatrek.
• Existing Little Green Pharma shareholders hold about 39.5% of the enlarged group.

May 2026 - Cann Group Chief Executive Steps Down

• Cann Group announced on 5 May 2026 that chief executive Jenni Pilcher had resigned and Mike Ryan became interim Executive Chairman.
• The company said debt fell from over A$70 million to under A$15 million and costs were cut by more than 60%.
• Production was set at a sustainable 7 to 8 tonnes of trimmed dried flower a year.

March 2026 - Little Green Pharma Terminates Facility Sale And Leaseback

• Little Green Pharma announced on 19 March 2026 that its A$7.8 million sale and leaseback of its south-west Western Australia production facility had terminated.
• The site includes a 1.3 tonne-a-year indoor cultivation facility and a GMP-compliant production facility, and remains company-owned.
• The company said the termination was not expected to affect operations.

Key Insight

Producers are consolidating and tightening leadership while keeping GMP sites in house. Stable, audited facilities sustain recurring batch release and stability programmes, even as competitive pressure builds.

Australia Medicinal Cannabis Testing Industry Segmentation

The Expert Market Research’s report on the Australia Medicinal Cannabis Testing Market offers a detailed analysis of the market based on the following segments.

Market Breakup by Test Type

• Potency and Cannabinoid Profiling
• Pesticide and Heavy Metal Residues
• Microbial and Mycotoxin Testing
• Residual Solvents
• Stability Testing and Others
• Others

Potency and Cannabinoid Profiling leads because every released batch must match its declared THC and CBD content, and the TGA's August 2025 paper flagged conflicting label information. Stability Testing and Others grows fastest at an estimated 11.4% CAGR through 2035, as ChemCentre's 2025 capability statement lists ICH stability studies and exporters need shelf-life evidence. Pesticide and Heavy Metal Residues tracks flower volumes. Microbial and Mycotoxin Testing rises with the vaping and confectionery-style products raised in the TGA's April 2026 feedback. Residual Solvents follows extract output. Others include terpenes and foreign matter.

Market Breakup by Sample Type

• Dried Flower
• Oils and Oral Liquids
• Extracts and Vape Products
• Capsules, Edibles and Other Formulations
• Others

Dried Flower leads because flower needs the widest panel of contaminant checks and is among the three most prescribed forms in the TGA's August 2025 paper. Capsules, Edibles and Other Formulations grows fastest at an estimated 10.2% CAGR through 2035, as Cann Group sells edibles and its July 2026 report noted clinics scrutinising higher-THC flower. Oils and Oral Liquids is the other major prescribed form, and Little Green Pharma's 72 products in market include many. Extracts and Vape Products includes concentrates reaching 88% THC by weight in the TGA's August 2025 paper, which require solvent and device-related checks.

Market Breakup by End User

• Licensed Cultivators and Manufacturers
• Importers and Sponsors
• Research and Academic Institutions
• Government and Regulatory Programs
• Others

Licensed Cultivators and Manufacturers lead because the Office of Drug Control's 2026 list shows 34 licence holders, 33 for cultivation and 20 for manufacture, and Little Green Pharma and Cann Group run GMP sites. Importers and Sponsors grow fastest at an estimated 9.9% CAGR through 2035, as the TGA's August 2025 paper proposed shifting responsibility from prescribers to sponsors and Vitura Health's Canview range lists roughly 600 products. Research and Academic Institutions buy specialised profiling for clinical work. Government and Regulatory Programs covers TGA surveillance and agencies such as the National Measurement Institute.

Market Breakup by Region

• New South Wales
• Victoria
• Queensland
• Western Australia
• South Australia
• Others (incl. Tasmania, ACT and Northern Territory)

Victoria dominates, anchored by Cann Group's Mildura GMP facility, Eurofins' South Dandenong pharmaceutical laboratory and Vitura Health's Melbourne distribution centre, and grows at an estimated 8.7% CAGR. Queensland is fastest at an estimated 9.3%, helped by Vitura's Gold Coast operations and Cann Group's supply agreements with eleven Chemist Warehouse outlets signed in April 2025. Western Australia grows at 8.9%, with ChemCentre in Bentley and Little Green Pharma's south-west facility. New South Wales, at 8.4%, is a large prescribing base. South Australia, at 8.2%, and Others, at 8.0%, are smaller.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Competitive Landscape in the Australia Medicinal Cannabis Testing Market

Competition combines government laboratories, international contract testers, in-house quality teams at licensed producers and instrument suppliers. Entry barriers include NATA accreditation, TGA licensing, validated methods for each dosage form and the trust of sponsors facing regulatory audit.

Little Green Pharma

Little Green Pharma, an ASX-listed medicinal cannabis company based in Western Australia, completed its Cannatrek acquisition on 1 June 2026, forming the LGP Cannatrek Group with AU-GMP certified manufacturing and 72 products across nine proprietary brands, according to its July 2026 investor presentation. It retained its 1.3 tonne-a-year south-west facility after a sale and leaseback ended in March 2026, and GMP production creates recurring release and stability testing needs.

Cann Group

Cann Group, an ASX-listed Victorian company, operates a cultivation and GMP manufacturing facility with integrated research near Mildura. Its quarterly report of 30 July 2026 recorded an A1 good compliance rating from a TGA GMP surveillance inspection, full-year receipts of A$10.03 million and first UK exports in the March 2026 quarter. Its Botanitech and Mallee Bloom brands cover dried flower, oils, vapes and edibles, each requiring batch release evidence.

Vitura Health

Vitura Health, an ASX-listed digital health and distribution company reporting from Melbourne, runs the Canview wholesale platform, with distribution centres in Melbourne and on the Gold Coast. Its results of 25 February 2026 showed half-year revenue of A$67.9 million, with Burleigh Heads Cannabis selling 507,799 units, and cited falling medicinal cannabis prices. As a large product supplier it faces sponsor-level quality obligations and sources batch evidence from producers.

ChemCentre

ChemCentre, a Western Australian government chemistry laboratory in the Resources and Chemistry Precinct at Bentley, holds a TGA manufacturing licence and GMP certification. Its 2025 capability statement lists TGO 93 medicinal cannabis testing, and its service covers cannabinoid profiles, terpenes, mycotoxins, heavy metals, pesticides, foreign matter, residual solvents and ICH stability studies, many NATA accredited. It also advises on formulation and analysis for cultivators.

Other players operating in the Australia medicinal cannabis testing market include Eurofins, the National Measurement Institute, Sigma Analytical Services, Novachem, and Agilent Technologies, alongside in-house quality teams, university laboratories and specialist contract analysts serving licensed producers and sponsors across Australia.

Key Insight

Competition rests on accreditation, validated methods and regulator trust rather than price alone. Government laboratories, global testers and in-house quality teams compete, and sponsors favour proven audit records.